

JCR 40th Anniversary: 40 years of Quality Delivery: The Legacy and Future

Katrien Remaut



Annual Meeting
AND Exposition

JULY 8-12, 2024 • BOLOGNA, ITALY

INTEGRATING
Delivery Science
ACROSS DISCIPLINES

1

From Antisense Oligonucleotide Degradation to Ocular mRNA Delivery: How the Journal of Controlled Release Shaped My Academic Journey

Katrien Remaut



Annual Meeting
AND Exposition


JULY 8-12, 2024 • BOLOGNA, ITALY

INTEGRATING
Delivery Science
ACROSS DISCIPLINES

2


1

My academic journey from PhD student to postdoc



3

Phase 1: Antisense oligonucleotides – degradation – FCS - nanoparticles



4

Phase 1: Antisense oligonucleotides – degradation – FCS - nanoparticles






Journal of Controlled Release
Volume 103, Issue 1, 2 March 2005, Pages 259-271



FRET-FCS as a tool to evaluate the stability of oligonucleotide drugs after intracellular delivery

K. Remaert, B. Lucas, K. Broeckmans, N.N. Sonders, S.C. De Smedt, J. Demester



R/G ratio ~ amount of intact ONs → measure degradation ifo time

5

Phase 1: Antisense oligonucleotides – degradation – FCS - nanoparticles



Journal of Controlled Release
Volume 110, Issue 1, 10 December 2005, Pages 222-226



Protection of oligonucleotides against nucleases by pegylated and non-pegylated liposomes as studied by fluorescence correlation spectroscopy

K. Remaert, B. Lucas, K. Broeckmans, N.N. Sonders, J. Demester, S.C. De Smedt



Journal of Controlled Release
Volume 117, Issue 2, 12 February 2007, Pages 256-266



Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides

K. Remaert, B. Lucas, K. Broeckmans, J. Demester, S.C. De Smedt






Journal of Controlled Release
Volume 164, Issue 1, 21 May 2010, Pages 65-74




Efficient delivery of intact phosphodiester oligonucleotides by poly-β-amino esters

K. Remaert, N. Symens, B. Lucas, J. Demester, S.C. De Smedt



Encapsulation efficiency and protection against degradation by lipid- and polymer based nanoparticles



Journal of Controlled Release
Volume 121, Issues 1-2, 16 August 2007, Pages 49-63



Can we better understand the intracellular behavior of DNA nanoparticles by fluorescence correlation spectroscopy?


K. Remaert, B. Lucas, K. Roemdonck, K. Broeckmans, J. Demester, S.C. De Smedt

6

Phase 2: Plasmid DNA – nuclear entry – autophagy - degradation – FCS - nanoparticles





Journal of Controlled Release
Volume 115, Issue 3, 27 October 2006, Pages 335-343



Influence of plasmid DNA topology on the transfection properties of DOTAP/DOPE lipoplexes

Kotrien Remaut, Niek N. Sonders, Farzaneh Fayazpour, Jozef Demeester,
Stefaan C. De Smedt [✉](#) [✉](#)



Nuclear delivery of plasmid DNA most efficient for SC pDNA and during cell division

7

Phase 2: Plasmid DNA – nuclear entry – autophagy - degradation – FCS - nanoparticles



Journal of Controlled Release
Volume 179, 10 April 2014, Pages 1-9



Journal of Controlled Release
Volume 179, 10 April 2014, Page 76

Cell division responsive peptides for optimized plasmid DNA delivery: The mitotic window of opportunity?

K. Remaut, N. Symens, B. Lucas, J. Demeester, S.C. De Smedt [✉](#) [✉](#)

No, but...

Cover story
The mitotic window of opportunity for plasmid DNA delivery

Kinom Park [✉](#)

The difficulties described in the study by Remaut et al. provide valuable lessons. Although the approach is sound, the results do not match the expectations. This means that there are many other factors that the authors did not consider, or the assumptions taken may not be the right ones. While the experiments need to be done by simplifying complex problems into an experimentally manageable one, such a process may unintentionally delete yet-unknown critical factors. Advancing science takes time, and requires unraveling the complexity of the intracellular environment step by step. The result of the study by Remaut et al. made one small step forward in knowledge, but the authors' attempt to describe the difficulties and problems made one large leap forward. It is time for many of us to stop highlighting only a marginal improvement, and discussing the real challenges to define the problems more clearly so that they can be solved.

Two strategies tested to enhance pDNA delivery during cell division

8

Phase 2: Plasmid DNA – nuclear entry – autophagy - degradation – FCS - nanoparticles






Journal of Controlled Release
Volume 195, 10 December 2014, Pages 29-36



Lysosomal capturing of cytoplasmic injected nanoparticles by autophagy: An additional barrier to non viral gene delivery

Katrien Remaut^a, Viola Oorschot^b, Kevin Braeckmans^a, Judith Klumperman^b,
Stefaan C. De Smedt^a



Chromatin targeting in artificial nuclei, but not upon microinjection in living cells → autophagy!

9

Phase 3: mRNA – degradation – FCS – lipid nanoparticles – ocular delivery - immunogenicity




Journal of Controlled Release
Volume 307, 10 August 2018, Pages 315-320



Non-viral delivery of chemically modified mRNA to the retina: Subretinal versus intravitreal administration

Jake Devolder^a, Karen Peetershoorn^a, Helene Dewitte^{a,b,c}, Christien Vanhooye^d, Lies De Groot^e,
Lieven Moens^f, Sümeyra Yılmaz Özcan^f, Deniz Dalkara^f, Stefaan C. De Smedt^a,
Katrien Remaut^a



Title: Non-viral delivery of chemically modified mRNA to induce protein expression in the retina
Journal of Controlled Release


Dear Dr Remaut,

Thank you for your interest in the Journal of Controlled Release. We have recently received two reviews of your manuscript.

Unfortunately, both of the reviewers felt that the manuscript was unsuitable for publication. Because of this ruling, and the large amount of manuscripts the journal receives, we regret to inform you that the Journal of Controlled Release is unable to publish your manuscript.

You may, however, consider resubmitting the work after full revision.

Inner limiting membrane is large barrier for intravitreal injected nanoparticles
Initial JCR rejection helped bringing the science to a better level



10

Phase 3: mRNA – degradation – FCS – lipid nanoparticles – ocular delivery - immunogenicity






Journal of Controlled Release
Volume 349, September 2022, Pages 315-326



ICG-mediated photodisruption of the inner limiting membrane enhances retinal drug delivery

Karen Pevenschoert^{a,b}, Helena Vanluchene^{a,b}, Koert De Clerck^{a,b}, An-Katrien Minnebo^{a,b}, Morgane Verhoeven^b, Noémie Goursaillou^c, Nezahat Bostan^c, Toshio Hisatomi^c, Geraldine Accou^c, Félix Sauvage^{a,b}, Kevin Braeckmans^{a,b}, Stefaan De Smedt^{a,b}, Katrien Remaert^{a,b}



Laser based strategy can make pores in the ILM to improve drug delivery

11

Conclusion



- JCR has shaped my contributions to science from PhD student to associate professor
- Reference journal for drug delivery and related technology
- I'm happy to contribute as
 - author (21% of my manuscripts are in JCR, responsible for 24% of my citations)
 - reviewer (60 completed assignments so far)
 - editorial board member



Katrien F. Remaert, PhD

Ghent University, Gent, Belgium

Non-viral gene delivery, mRNA, ocular administration, peritoneal carcinomatosis

12

Acknowledgements

